News & Events

Latest news from Inhalation Sciences

April 13, 2010
GSK and Inhalation Sciences Sweden AB have entered a collaboration aiming at evaluating the safety and performance of the DustGun aerosol technology when integrated in a preclinical platform containing in vitro, ex vivo and in vivo exposure models.

July 1, 2009
Inhalation Sciences Sweden AB enters a service for fee assignment with Schering Plough.

July 1, 2008
Inhalation Sciences Sweden AB and AstraZeneca AB enter a postdoc collaboration agreement aiming at validating the DustGun system for preclinical use with the isolated perfused lung system and in vivo exposures to generate early pharmacokinetic and dynamic data for drug selection and formulation optimization during the early drug development process.

October 1, 2007
Inhalation Sciences Sweden AB and AstraZeneca AB enter a research collaboration aiming at building a better understanding of the relationship between dissolution rate and the absorption/ retention of drug substance after local deposition in the lung using the Disolvit System.

Experimental Approaches to Assess Particle Dissolution Rate In Vitro and Ex Vivo

The International Conference of the American Thoracic Society (ATS) 2009, San Diego, May 15th - May 20th, 2009

Inhalation Sciences Sweden AB will presented a poster entitled: “Experimental Approaches to Assess Particle Dissolution Rate In Vitro and Ex Vivo”

P Ewing2, M Börjel1, S Eirefelt2, A Tronde2, A Miller-Larsson2, S Edsbäcker2, B Olsson2, Å Ryrfeldt1, K Ekelund2 and P Gerde1

1) Inhalation Sciences AB, Stockholm, Sweden 2) AstraZeneca R&D Lund, Lund, Sweden

Vasoconstriction after inhalation of budesonide: a study in the isolated and perfused rat lung

September, 2009

Pär Ewing1,4*, Åke Ryrfeldt1, Carl-Olof Sjöberg2, Paul Andersson3, Staffan Edsbäcker4 and Per Gerde1,5

1) National Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
2) Flexura KB, Stockholm, Sweden 3) Discovery DMPK and Bioanalysis, AstraZeneca R&D Lund, Lund, Sweden 4) Clinical Pharmacology, AstraZeneca R&D Lund , Lund, Sweden 5) Inhalation Sciences AB, Stockholm, Sweden

Accepted for Publication in Pulmonary Pharmacology & Therapeutics 2009

Conclusions: Inhaled budesonide rapidly induces pulmonary vasoconstriction suggesting a non-genomic mechanism probably related to disposition of noradrenaline at the neuro-muscular junction. This ex vivo model could serve as a substitute or a complement to clinical models for investigating rapid effects of glucocorticoid receptor agonists on the pulmonary/bronchial circulation.

Experimental approaches to assess particle dissolution rate in vitro and ex vivo

May, 2009

Pär Ewing2*, Maria Börjel1, Stefan Eirefelt2, Ann Tronde2, Anna Miller-Larsson2, Staffan Edsbäcker2, Bo Olsson2, Åke Ryrfeldt1,3, Katarina Ekelund2 and Per Gerde1,3

1) Inhalation Sciences AB, Stockholm, Sweden; 2) AstraZeneca R&D Lund, Lund, Sweden; 3) Karolinska Institutet, Stockholm, Sweden; *Presenting author par.ewing@astrazeneca.com

Presented at The International Society for Aerosols in Medicine, May 10-14, 2009, Monterey, CA

Conclusions

  • In the IPL, the mean pulmonary absorption time of fluticasone propionate is markedly greater than that of budesonide. These data agree closely with historic in vivo PK data in humans.
  • As suggested by Dissolvit results, the rate determining factor in the pulmonary absorption of fluticasone propionate is most likely slow particle dissolution.
  • The DissolvIt system can be a valuable tool for predicting dissolution time of inhaled pharmaceutical particles in the lung.
  • To further validate these preliminary data more compounds as well as different formulations of identical compounds should be investigated.

Permeability to Macromolecules: Characterisation in the Perfused and Ventilated Rat Lung (IPL) Exposed to Inhaled Horseradish Peroxidase

International Society for Aerosols in Medicine (ISAM): The 17th International Congress Monterey, California, USA, May 10-14, 2009

Inhalation Sciences Sweden AB presented a poster entitled: “Permeability to Macromolecules: Characterisation in the Perfused and Ventilated Rat Lung (IPL) Exposed to Inhaled Horseradish Peroxidase “

E Selg1, F Acevedo1, B Blomgren3, Å Ryrfeldt2, P Gerde1,2

1Inhalation Sciences AB and 2Karolinska Institutet, Stockholm, Sweden 3AstraZeneca, Södertälje, Sweden

Inhaled budesonide causes rapid vasoconstriction in the isolated and perfused rat lung

The European Respiratory Society Annual Meeting October 4--8, 2008, in Berlin, Germany.

Per Gerde of Inhalation Sciences Sweden AB presented “Inhaled budesonide causes rapid vasoconstriction in the isolated and perfused rat lung”.

Poster session: P3652. P. Ewing, C. O. Sjöberg, P. Andersson, S. Edsbäcker, A. Ryrfeldt, P. Gerde (Lund, Stockholm, Sweden)